Press release
Familial Amyloid Neuropathies - Pipeline Review, H1 2017: Pharmaceuticals Industry Research Report – MRH
Pharmaceutical Industry Research Reports - MRH
Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1196665
Familial amyloid neuropathy is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues. Symptoms include numbness, tingling, pins and needles in the feet and hands, weakness and pain in the arms and legs, loss of sensation, urinary retention, reduced sweating, ankle swelling, fatigue, nausea, weight loss, dizziness and fainting. Supportive treatment includes diuretics, calcium channel blockers, beta blockers, angiotensin receptor blockers and angiotensin converting enzyme (ACE) inhibitors.
The Familial Amyloid Neuropathies (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Familial Amyloid Neuropathies and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.
Familial Amyloid Neuropathies (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Market Research HUBs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Make An Enquiry: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1196665
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Familial Amyloid Neuropathies (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Familial Amyloid Neuropathies (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Familial Amyloid Neuropathies (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Familial Amyloid Neuropathies (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Familial Amyloid Neuropathies (Metabolic Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Familial Amyloid Neuropathies (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Familial Amyloid Neuropathies (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Browse Full Report With TOC: http://www.marketresearchhub.com/report/familial-amyloid-neuropathies-pipeline-review-h1-2017-report.html
About Market Research Hub:
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
Contact Us
90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email: press@marketresearchhub.com
Website: http://www.marketresearchhub.com/
Read Industry News At: https://www.industrynewsanalysis.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Familial Amyloid Neuropathies - Pipeline Review, H1 2017: Pharmaceuticals Industry Research Report – MRH here
News-ID: 603840 • Views: …
More Releases from Medical Industry Analysis Reports - MRH
Global Scoop Stretcher Sales Market Anticipated to Expand at a CAGR of 2.51% bet …
This report studies the Scoop Stretcher Market Status and Outlook of global and major regions, from angles of players, regions, product types and end industries; this report analyzes the top players in global and major regions, and splits the Scoop Stretcher market by product type and applications/end industries.
Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1211022
The global Scoop Stretcher market was estimated at 248.06 Million USD in 2016 and is anticipated to expand at…
Global Prostaglandin Market Research Report 2017: Market Analysis Revealing Key …
A latest research report titled as ”Global Prostaglandin Market Research Report 2017” has been recently added to the vast portfolio of Market Research Hub (MRH) online research offerings. This report is a professional and in-depth analysis on the present state and future prospect for the global market. It provides valuable information to the industry insiders, potential entrants or investors. It includes an exhaustive enquiry with the reliability of logic and…
Global Ingestible Sensors Market Forecasted to Gain Steady Growth at a CAGR of 2 …
The report titled, “Global Ingestible Sensors Market: Analysis By Sensor Type (Temperature, Pressure, Image, pH), By Sensor Application (Medical, Sports & Physical Fitness), By Region, By Country: Opportunities and Forecast (2017-2022)” has covered and analysed the potential of Global Ingestible Sensors Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation.…
Global Low Trauma/Skin Friendly Adhesives Market Research Report 2017: Industry …
A latest research report titled as ”Global Low Trauma/Skin Friendly Adhesives Market Research Report 2017” has been recently added to the vast portfolio of Market Research Hub (MRH) online research offerings. This report is a professional and in-depth analysis on the present state and future prospect for the global market. It provides valuable information to the industry insiders, potential entrants or investors. It includes an exhaustive enquiry with the reliability…
More Releases for Familial
Familial Adenomatous Polyposis (FAP) Therapeutics- Pipeline Analysis 2018
Familial adenomatous polyposis (FAP) is a genetic disorder, characterized by the development of adenomatous colon polyps in the intestinal tract, resulting in colon cancer. The disease is diagnosed when more than 100 adenomatous colon polyps are developed in a person.
Download the sample report at: https://www.pharmaproff.com/request-sample/1025
A person with FAP is at a high risk of developing cancer of small intestines or stomach. This disease is categorized into three types including attenuated…
Familial Amyloid Cardiomyopathy Treatment Market Opportunity Analysis, 2018–20 …
Aggregation and deposition of mutant and wild-type transthyretin protein (TTR) in heart results in familial amyloid cardiomyopathy, which typically occur after age of 60. Familial amyloid cardiomyopathy is also known as hereditary cardiac transthyretin amyloidosis or hereditary amyloid cardiomyopathy. The protein transthyretin amyloid fibrils infiltrate the myocardium that leads to diastolic dysfunction from restrictive cardiomyopathy, which eventually result to heart failure. There are several mutation in TTR which are associated…
Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2017
Market Research Hub's latest Pharmaceutical and Healthcare disease pipeline guide “Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review”, H2 2017, provides an overview of the Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline landscape.
Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder caused due to a mutation (alteration) of FH from one (affected) parent. Symptoms include xanthesmas, corneal arcus, aortic rupture and peripheral vascular disease. Risk factors include age, sex, smoking and hypertension,…
Familial Adenomatous Polyposis - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Familial Adenomatous Polyposis - Pipeline Review, H2 2017 to its growing collection of premium market research reports.
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Familial Adenomatous Polyposis - Pipeline Review, H2 2017, provides an overview of the Familial Adenomatous Polyposis (Genetic Disorders) pipeline landscape.
Familial adenomatous polyposis (FAP) or classic FAP is a genetic condition that causes extra…
Familial Chylomicronemia Syndrome Treatment Market
Familial Chylomicronemia Syndrome is a genetic condition characterized by an inability of the body to digest fats mainly triglyceride. In Familial Chylomicronemia Syndrome, the lipoprotein lipase (LPS) is not functional, which is the enzyme that breaks down chylomicrons in the blood. The most distinctive sign of Familial Chylomicronemia Syndrome is the appearance of fatty blood on the skin, mainly owing to high level of fat in the body. People with…
Familial Adenomatous Polyposis - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Familial Adenomatous Polyposis - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Familial Adenomatous Polyposis - Pipeline Review, H1 2017, provides an overview of the Familial Adenomatous Polyposis (Genetic Disorders) pipeline landscape.
Familial adenomatous polyposis (FAP) is also known as familial polyposis coli, adenomatous polyposis coli, or…
